Strides Pharma Science on Wednesday said its unit has received approval from the US health regulator to market a generic medication used in the treatment of gastrointestinal diseases. Singapore-based Strides Pharma Global Pte. Ltd, has received approval for the generic version of Sucralfate Oral Suspension, 1gm/10 mL, from the US Food & Drug Administration (USFDA), the drug firm said in a statement.
The product is bioequivalent and therapeutically equivalent to AbbVie’s Carafate (1gm/10mL).
Sucralfate is used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis, and stomach inflammation and to prevent stress ulcers.
As per IQVIA, Sucralfate Oral Suspension (1gm/10 mL) had a market size of USD 124 million in the US market.
Shares of the company were trading 6.33 per cent up at Rs 899.75 apiece on the BSE.
